Department of Pathology and Laboratory Medicine, Indiana University, IU Health Pathology Laboratory, 350 W 11th Street, Room 4086, Indianapolis, IN 46202, USA.
Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Pathology Unit #085, Houston, TX 77030, USA.
Surg Pathol Clin. 2024 Mar;17(1):119-139. doi: 10.1016/j.path.2023.06.009. Epub 2023 Aug 5.
Sclerosing epithelioid fibrosarcoma (SEF) is a distinctive sarcoma that may arise in nearly any soft tissue site or bone. While there has been past controversy as to whether it is related to low-grade fibromyxoid sarcoma (LGFMS), it has been shown to behave far more aggressively than LGFMS. SEF has a propensity to metastasize to the lungs and bone and arise within the abdominal cavity. Histologically, it is characterized by uniform nuclei embedded in a densely collagenous stroma simulating osteoid. By immunohistochemistry, it is often strongly positive for MUC4. The majority (75%) have EWSR1 gene rearrangement, most commonly with CREB3L1 as a fusion partner, although a variety of FUS/EWSR1 and CREB3L1/CREB3L2/CREB3L3 fusions have been described in addition to others. SEF is currently recalcitrant to nearly all chemotherapy and radiation therapy.
硬化性上皮样纤维肉瘤(SEF)是一种独特的肉瘤,可能发生在几乎任何软组织部位或骨骼中。虽然过去曾有争议认为它是否与低度纤维黏液样肉瘤(LGFMS)有关,但现已表明其行为远比 LGFMS 更为激进。SEF 有向肺部和骨骼转移以及在腹腔内发生的倾向。组织学上,其特征为均匀的细胞核嵌入在密集的胶原基质中,模拟成骨。通过免疫组织化学,它通常强烈表达 MUC4。大多数(75%)患者存在 EWSR1 基因重排,最常见的融合伙伴是 CREB3L1,尽管除了其他融合伙伴外,还描述了各种 FUS/EWSR1 和 CREB3L1/CREB3L2/CREB3L3 融合。SEF 目前几乎对所有化疗和放疗均有抗性。